0.50 / AMA PRA Category 1 Credit(s)TM 0.50 / Contact Hours
Provided by The Academy for Continued Healthcare Learning
Supported by an educational grant from Ferring Pharmaceuticals, Inc.
This interview with Dr. Sahil Khanna provides insights on the problem of recurrent C. difficile infection. In this Q&A format, Dr. Khanna will review selection of antimicrobial therapy for recurrent C. difficile, its impact on the role of the gut microbiome in C. difficile infection, and microbial restoration therapies under investigation.
This educational activity is designed for physicians, pharmacists, nurse practitioners, physician assistants, nurses and other clinicians who care for patients at risk of serious gastrointestinal infection.
At the conclusion of this activity, participants should be better able to:
Evaluate the role of the gut microbiome in relationship to C. difficile infection and approaches to restoration for prevention of recurrent infection
Describe available and emerging approaches for patients with recurrent C. difficile who have failed appropriate antibiotic therapy
Conflict Of Interest Disclosure Policies
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity.
Sahil Khanna, MBBS, MS Associate Professor of Medicine Gastroenterology and Hepatology Mayo Clinic Rochester, MN
Dr.Khanna Sources of Funding for Research: Ferring Pharmaceuticals, Inc., Rebiotix, Inc Consulting Agreements: Facile Therapeutics, Inc., Premier Inc., Probiotech LLC, Shire PLC
Kelly Osborne, MSN, APRN, AGCNS-BC, CGRN, CFER (Nurse planner) Clinical Nurse Specialist Duke University Health System Division of Gastroenterology Durham, NC
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Contact Hour(s)
This continuing nursing education activity was approved by the Ohio Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. (OBN-001-91) Activity #22864
A maximum of 0.50 contact hours may be earned for successful completion of this activity.
There is no conflict of interest for anyone with the ability to control content for this activity.
Disclosure of Unlabeled Use
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Investigational approaches to treating C. difficile infection and reducing recurrent episodes.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Your online certificate will be saved on myCME within your Profile/Exam History, which you can access at any time.
For questions, contact Melissa Stradal at 773-714-0705 x 160.